EuroPCR 2020 | EVOQUE: New Transcatheter Mitral Valve Replacement System, Promises at Short Term and Future Hope

Transeptal transcatheter mitral valve replacement offers a less invasive alternative vs. surgery and with fewer anatomical limitations than transcatheter repair (e.g. MitraClip) in patients with severe mitral valve failure. 

EuroPCR 2020 | EVOQUE: nuevo sistema de reemplazo mitral por catéter, promesas a corto plazo y esperanzas para el futuro

The first patients treated with the new system EVOQUE were included between September 2018 and October 2019 and its outcomes were presented at the virtual EuroPCR 2020 and were simultaneously published in JACC: Cardiovascular Interventions.

Inclusion criteria were moderate to severe Mitral failure, functional class II or higher and high or prohibitive surgical risk. Primary end point was technical success according to the Mitral Valve Academic Research Consortium criteria.

Fourteen patients with mean age 84 and 4.6% STS (it was a “first in human” study) were included. Mitral failure resulted at least moderate to severe in all of them, even though etiology varied (28.6% degenerative, 21.4% functional and 50% mix).


Read also: EuroPCR 2020 | Sudden Death Increase Two to Three Times While MI Rate Falls.


Technical success was achieved in 92.9% of the population. The only patient that could not receive the device received surgery.

At 30 days, one patient died of non-cardiovascular causes (7.1%) and there were two strokes (14.3%). There were no infarctions or rehospitalizations. 

One patient underwent alcohol septal ablation for left ventricular outflow tract obstruction and two required paravalvular leak closure. Despite this, at 30 days all patients presented mild mitral failure and, in fact, over 80% of the population presented no mitral failure at all. 

Conclusion

This first test in humans for the transseptal EVOQUE mitral valve device showed feasibility. We need more time and further research to determine its clinical safety and efficacy. 

EVOQUE

Original Title: Transcatheter Mitral Valve Replacement with the Transseptal EVOQUE System.

Reference: J. Webb et al. JACC: Cardiovascular Interventions 2020, article in press. doi: https://doi.org/10.1016/j.jcin.2020.06.040 y presentado en el EuroPCR virtual 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...